To be diagnosed with a substance use disorder, a person must meet specific diagnostic criteria for continued substance use despite negative consequences. Finding long-lasting treatment options for mental health disorders, including addiction, is complicated and met with various challenges. The use of psychedelics in treatment is getting more attention as recent research suggests efficacious treatment outcomes in specific behavioral health disorders. In another study, researchers examined the feasibility and safety of using psilocybin treatment to treat smoking dependence.18 Fifteen nicotine-dependent smokers were included in the trial.
Professional development
Here, recent studies demonstrating the diverse pharmacological effects of psychedelics in mental disorders are reviewed, and emerging perspectives on structural function, the microbiota‐gut‐brain axis, and the transcriptome are discussed. Moreover, the applicability of deep learning is highlighted for the development of drugs on the basis of big data. These approaches may provide insight into pharmacological mechanisms and interindividual factors to enhance drug discovery and development for advanced precision medicine. There are several examples of successful evidence of drug discovery via DL.199, 213 DeepDTnet was used to predict the identification of targets and repurposed drugs via a drug‒gene‒disease network. In particular, three drugs, alisporivir, Cyclosporine, and Voclosporin, have critical functions in the life cycle of coronaviruses as cyclophilin enzyme inhibitors.
- Participants attended four weekly meetings during which Cognitive-Behavioral Therapy was delivered.
- In one trial, a single dose of 25 mg significantly reduced symptom severity compared with placebo.
- Physical symptoms, such as nausea and vomiting, may also occur after taking a psychedelic.
- Traditional treatments may include antidepressant medications and psychotherapy.
- Since psychedelics have such powerful effects, even in double-blind studies, it’s apparent to subjects and investigators who have received the study drug and who have received the placebo.
As mentioned, most studies recruited relatively small samples which prevents applicability in other research settings. Psilocybin was designated a breakthrough therapy designation by the Food and Drug Administration (FDA) in 2018, 2019, and 2024 owing to its potency for monotherapy or combination treatment.107 Several types of psilocybin‐assisted therapies are currently in clinical trials. Psilocybin studies have found that 71% of individuals with major depressive disorder who received two doses of psilocybin responded to treatment, and half entered remission.
These substances can have powerful effects on the mind, which some people crave. Some may have legitimate medical uses, but there are still significant risks like addiction you must consider. In June 2022, NIDA’s Office of Translational Initiatives and Program Innovations also announced a new program to support small businesses to develop psychedelic-based therapies for substance use disorders. Mingon Kang obtained his Ph.D. and master’s degrees from The University of Texas at Arlington in 2015 and 2010, respectively.
- “Erowid created an environment for people to connect and share information, but also one for younger people, experimenting for the first time, to meet the equivalent of the older brother who’s already into the scene.”
- Common to all these papers are those user-submitted reports in the Experience Vault.
- Professionals also monitor vital signs while using psychedelics during therapy.
- In the U.S., psychedelic-assisted therapy is still in the clinical trial stage.
Law enforcement seizures of psilocybin mushrooms rose dramatically between 2017-2022
Here, a very recent view of the respective psychedelics may provide insight for further research accompanied by experiments in rodent models (Table 1) and clinical trials in patients (Table 2) with mental disorders (Figure 2). Alongside CYB003, several other psychedelic compounds are advancing toward late-stage clinical development for mental health disorders (Table 1). In June 2025, Compass Pathways announced that COMP360, a proprietary psilocybin formulation, demonstrated positive data in its double-blinded phase 3 trials for treatment-resistant depression. In one trial, a single dose of 25 mg significantly reduced symptom severity compared with placebo. A second phase 3 trial is now exploring whether this response is dose dependent, testing doses of 25 mg, 10 mg and 1 mg.
A pharmacist’s job entails knowing the difference and helping patients understand the risks. This involves careful screening for a patient’s history of substance misuse and providing clear guidance on each substance’s unique safety profile. This dissociative drug is not controlled under the Federal Controlled Substances Act but is banned or regulated in several states. Prolonged use of DXM can lead to abuse and addiction and result in withdrawal symptoms if the user cannot continue using the drug. Ketamine is a Schedule III controlled substance in the United States, indicating a potential for moderate to low physical dependence or high psychological dependence.
Addiction to other substances, such as opioids, cocaine, or methamphetamine, can also be considered for psychedelic therapy. Similar to alcohol addiction recovery, the goal of treatment is to break addictive patterns and support long-term recovery goals. Significant reductions in PTSD symptoms were reported in a study published in the Canadian Medical Association Journal.
Video: Depression 101
Better understanding these mechanisms is an active area of NIDA-funded research. This basic research plays an important role in identifying their health effects and potential therapeutic uses. It is important to find long-lasting treatment options for addiction and mental health disorders. While more research is being conducted on the use of psychedelics as therapeutic treatment, it is vital to move ahead with care and to focus on the scientific rigor of the research. Further clinical research is necessary to establish which psychedelic drugs are most effective, how they should be administered, and who is most likely to benefit.
BBC Click visits CES 2025 to find out about the latest health tech, from medical tools to well-being devices. Researchers say that this process means Erowid’s Vaults are more stringently reviewed when compared to other websites and, although all are anecdotal, they provide a solid baseline reference for researchers. Yet Erowid was, at first, a small, isolated community predominantly for data geeks and drug nerds.
How many people use hallucinogens*?
Mental disorders are a representative type of brain disorder, including anxiety, major depressive depression (MDD), and autism spectrum disorder (ASD), that are caused by multiple etiologies, including genetic heterogeneity, epigenetic dysregulation, and aberrant morphological and biochemical conditions. Psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have been renewed as fascinating treatment options and have gradually demonstrated potential therapeutic effects in mental disorders. However, the multifaceted conditions of psychiatric disorders resulting from individuality, complex genetic interplay, and intricate neural circuits impact the systemic pharmacology of psychedelics, which disturbs the integration of mechanisms that may result in dissimilar medicinal efficiency. The precise prescription of psychedelic drugs remains unclear, and advanced approaches are needed to optimize drug development.
Participants in the study also stated they had very few adverse effects while using psychedelics as part of their treatment for PTSD. As research continues to unveil the significant effects these substances can have on the human mind, therapists and patients alike are discovering the transformative potential of psychedelics to heal trauma, alleviate depression, and provide profound personal insights. In the quiet, dimly lit room, a patient sits comfortably, surrounded by soft music and gentle voices guiding them through a journey of self-discovery. This isn’t a scene from a science fiction novel but a groundbreaking approach to mental health treatment known as psychedelic-assisted therapy.
In Cybin’s phase 2 trial with CYB003 (a compound derived from psilocybin, a hallucinogenic alkaloid found in ‘magic mushrooms’), 75% of patients with treatment-resistant depression achieved remission after just two doses, with 71% maintaining that remission a year later despite receiving no further treatment. These results remain unpublished, but CYB003 received US Food and Drug Administration (FDA) Breakthrough Therapy designation based on these results, and Cybin has phase 3 trials underway, with the first readout expected toward the end of 2026. Today, the psychedelic science industry is reportedly worth $3bn (£2.25bn) and only growing. A clinical research renaissance is currently underway into the effects of powerful hallucinogens like ketamine, dimethyltryptamine (DMT), “magic” mushrooms and MDMA (also known as molly or ecstasy), exploring their potential to treat afflictions like depression, post-traumatic stress disorder and addiction. Pharmacists can use this mistaken belief as an opportunity to provide clarity and a chance to educate. It is important to understand that psychedelic medicine is not meant to take the place of existing treatments.
Today, compounds derived from psychoactive substances such as psilocybin and lysergic psychedelic and dissociative drugs acid diethylamide (LSD) are the subject of some of the most closely watched psychiatric drug trials. Early results suggest they may offer relief where conventional treatments fail. Clinically, psychedelic drugs are a group of drugs that primarily influence the manner in which the brain processes the chemical serotonin resulting in vivid visions and affecting a person’s sense of self1. Examples of psychedelic drugs are psilocybin (magic mushrooms), lysergic acid diethylamide (LSD), N, N-dimethyltryptamine (DMT), mescaline, and N-Benzylphenethylamines (NBOMes)1.
NIDA supports and conducts research to learn whether some of these drugs may help treat substance use disorders in medical settings. Professionals also monitor vital signs while using psychedelics during therapy. A person’s heart rate and blood pressure may increase, especially during moments of heightened anxiety.
While short-term positive and negative mood changes are common with psychedelic and dissociative drugs, more research is needed to better understand the long-term effects these substances may have on mental health. Studies on animal and human subjects have proven that psychedelics can produce long-term behavioral effects. The compounds can have a direct impact on depression, anxiety, and other psychiatric disorders. Neuroimaging studies performed during clinical trials have demonstrated that psychedelics can alter functional connectivity in the brain, including decreasing connectivity within the DMN.